Top Markets
Coin of the day
OmniAb, Inc. OmniAb, Inc.

OmniAb, Inc.

OABI
Kedudukan dalam Saham #11871
OmniAb, Inc. is an American biotechnology firm focused on pioneering... OmniAb, Inc. is an American biotechnology firm focused on pioneering therapeutic antibody discovery. The company provides a sophisticated platform that allows its industry partners to access a broad spectrum of antibody repertoires and advanced screening techniques, thereby facilitating the development of next-generation treatments. Central to the OmniAb platform is the unique biological capability of proprietary genetically engineered animals, such as OmniRat, OmniChicken, and OmniMouse. These animals are modified to produce human-sequence antibodies, simplifying the creation of human therapeutic candidates. Additionally, OmniAb offers specialized technologies like OmniFlic (a transgenic rat) and OmniClic (a transgenic chicken), which address the requirements for bispecific antibody applications via a common light chain method, as well as OmniTaur, which leverages the distinct structural properties of cow antibodies for challenging targets. The company was founded in 2012 and is based in Emeryville, California.
Harga Saham
$4.48
Disegerakkan terakhir: 2026-08-28
Modal Pasaran
$649.33M
Perubahan (1 hari)
-2.84%
Perubahan (1 tahun)
179.94%
Negara
US
Perdagangan OmniAb, Inc. (OABI)

Kategori

Hasil untuk OmniAb, Inc. (OABI)
Hasil pada Aug 2026 TTM: 0
Menurut laporan kewangan terkini daripada OmniAb, Inc., hasil semasa syarikat (TTM) ialah 0. Pada tahun 2026, syarikat memperoleh hasil sebanyak 0 sama dengan hasil pada tahun 2026 iaitu 0. Hasil ialah jumlah pendapatan keseluruhan yang dijana oleh syarikat daripada jualan barangan atau perkhidmatan. Tidak seperti keuntungan, tiada perbelanjaan ditolak.
Sejarah hasil bagi OmniAb, Inc. dari 2026 hingga 2026
Hasil pada akhir setiap tahun
Tahun Hasil Ubah
Tidak cukup data untuk tarikh yang disediakan.
Hasil untuk syarikat atau pesaing serupa
Syarikat Hasil Perbezaan Hasil Negara
$12.62B -
US
$6.02B -
NL
$15.74B -
AU
$2.23B -
US
- -
CH